CVRx, Inc. CVRX

Company Overview

CVRx, Inc. is a U.S.-based medical device company focused on developing and commercializing neuromodulation therapies for cardiovascular diseases. The company operates within the medical technology and cardiovascular device industries, with its primary commercial product being the Barostim platform, an implantable device designed to deliver baroreflex activation therapy (BAT). CVRx primarily targets patients with heart failure and related cardiovascular conditions, particularly individuals with heart failure with reduced ejection fraction who remain symptomatic despite guideline-directed medical therapy. Revenue is primarily generated through sales of the Barostim system, related implantation procedures, and associated physician and hospital adoption programs.

The company was founded in 2001 and is headquartered in Minneapolis, Minnesota. CVRx spent much of its early history focused on clinical development, regulatory approvals, and long-term cardiovascular outcome studies related to baroreflex activation therapy. A significant milestone occurred when the U.S. Food and Drug Administration approved the Barostim Neo System in 2019 for heart failure patients. The company’s strategic positioning is based on its specialization in device-based neuromodulation therapy for cardiovascular disease, an area with relatively limited direct competition compared with more established cardiac rhythm management and structural heart device categories.